Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis

Iwamoto, Jun; Takeda, Tsuyoshi; Ichimura, Shoichi; Matsu, Kenjiro; Uzawa, Mitsuyoshi

doi:10.1007/s00776-003-0655-5

Cited by 31 publications

(25 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The level of musculoskeletal pain was not correlated with body composition such as muscle mass and fat percentile either. Some studies have shown improvements on the lumbar pain scale that significantly correlated with the percentage change of urinary N-telopeptide and with increased BMD in bisphosphonate-treated patients [10,11]. Although our study results did not show any significant correlation between BMD and musculoskeletal pain, we did not evaluate the bone turnover markers, which reflect dynamic changes in BMD.…”

Section: Discussioncontrasting

confidence: 72%

See 1 more Smart Citation

Bone mineral density is not associated with musculoskeletal pain in postmenopausal Korean women aged ≥50 years

et al. 2014

View full text Add to dashboard Cite

Although many studies reported improvement of back pain after osteoporosis treatment, there is insufficient evidence to determine whether osteoporosis is painful. We investigated whether bone mineral density correlated with musculoskeletal pain in postmenopausal Korean women aged ≥50 years. Data for postmenopausal women aged ≥50 years were obtained from the fifth Korea National Health and Nutrition Examination Survey database. Demographics, Kellgren-Lawrence grade, and numeric rating scale for pain in the hip and knee joints, presence of back pain, and activity level were analyzed. Only subjects with dual-energy X-ray absorptiometry scans and hip and knee radiographs were included. Those with malignancy, pain medication use, or a history of fragility fractures were excluded. After univariate analysis, multiple linear regression analysis was performed to examine the significant factors correlated with the degree of hip and knee pain. Binary logistic regression analysis was performed to identify factors significantly associated with the presence of back pain. In total, 387 women were included in the data analysis. Age (p = 0.005) was the only significant factor correlated with the intensity of hip pain, while Kellgren-Lawrence grade (p < 0.001) was the only significant factor correlated with knee pain intensity in multiple regression analysis. Binary logistic regression analysis showed that age (p = 0.002) was the only significant factor associated with the presence of back pain. Musculoskeletal pain was not affected by or associated with the bone mineral density (BMD) of the affected body part in postmenopausal Korean women aged ≥50 years after adjusting for the degree of osteoarthritis.

show abstract

Section: Discussioncontrasting

confidence: 72%

“…In addition, several studies investigating "osteoporotic pain" have reported a reduction in back pain after receiving osteoporosis medication [9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24], suggesting a close relationship between osteoporosis and back pain.…”

Section: Introductionmentioning

confidence: 99%

Bone mineral density is not associated with musculoskeletal pain in postmenopausal Korean women aged ≥50 years

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Miller et al [12] reported that ALN was inferior to teriparatide in preventing back pain in the long-term in postmenopausal women with osteoporosis. In our clinical experience, however, bisphosphonates such as etidronate and ALN rapidly decrease bone turnover and relieve back pain in postmenopausal women with osteoporosis [13][14][15][16]. A recent observational study showed the acute effect of risedronate on back pain, disability, and QOL (SF-36) in postmenopausal osteoporotic women without any vertebral fracture [17].…”

Section: Introductionmentioning

confidence: 98%

Alendronate is more effective than elcatonin in improving pain and quality of life in postmenopausal women with osteoporosis

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Eine sinnvolle Dosierung scheint bei 0,5 bis 1,0 mg t€ aglich zu liegen, da für diese Dosierungen -allerdings meist in Kombination mit Kalzium und/ oder anderen knochenwirksamen Substanzen -Daten für postmenopausale Frauen vorliegen [163][164][165][166][167][168]. Zur Erreichung eines optimalen Therapieeffekts ist auch hier auf eine ausreichende Kalziumzufuhr zu achten.…”

Section: Therapiedauerunclassified

Österreichischer Leitfaden zur medikamentösen Therapie der postmenopausalen Osteoporose – Update 2009

Dimai

Pietschmann

Resch

et al. 2009

Wien Med Wochenschr

View full text Add to dashboard Cite

Osteoporosis is a systemic skeletal disease characterized by diminished bone mass and deterioration of bone microarchitecture, leading to increased fragility and subsequent increased fracture risk. Therapeutic measures therefore aim at reducing individual fracture risk. In Austria, the following drugs, all of which have been proven to reduce fracture risk, are currently registered for the treatment of postmenopausal osteoporosis: alendronate, risedronate, etidronate, ibandronate, raloxifene, teriparatide (1-34 PTH), 1-84 PTH, strontium ranelate and salmon calcitonin. Fluorides are still available, but their role in daily practice has become negligible. Currently, there is no evidence that a combination of two or more of these drugs could improve anti-fracture potency. However, treatment with PTH should be followed by the treatment with an anticatabolic drug such as bisphosphonates. Calcium and vitamin D constitute an important adjunct to any osteoporosis treatment.

show abstract

Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis

Cited by 31 publications

References 20 publications

Bone mineral density is not associated with musculoskeletal pain in postmenopausal Korean women aged ≥50 years

Bone mineral density is not associated with musculoskeletal pain in postmenopausal Korean women aged ≥50 years

Alendronate is more effective than elcatonin in improving pain and quality of life in postmenopausal women with osteoporosis

Österreichischer Leitfaden zur medikamentösen Therapie der postmenopausalen Osteoporose – Update 2009

Contact Info

Product

Resources

About